HealthLeaders Media January 14, 2020
John Commins

The commitment includes a $200 million immunotherapy-focused partnership with the University of Pittsburgh.

KEY TAKEAWAYS

– UPMC Enterprises has created five companies in translational sciences and invested in an external biotech company and more than 30 research projects.

– UPMC has invested more than $800 million, primarily in digital health solutions, which have returned more than $1.5 billion.

UPMC Enterprises said Tuesday that it will “deploy” $1 billion to develop new drugs, diagnostics and medical devices over the next four years.

“The common link among our investments will be that each has a direct and powerful impact on how we care for patients, while generating a significant financial return,” UPMC Enterprises Executive Vice President Jeanne Cunicelli said in a media...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Health IT, Health System / Hospital, Investments, Provider, Technology, Trends
Physician Compensation Continues To Decline, Despite A Dire Shortage
AI expertise gets more expensive as hospitals bulk up
How to bridge the experience gap by supporting nurses of all tenures
Understanding CMS’ AHEAD Model: Medicare Hospital Global Budget Design and Implications
AI nurses? Inside Nvidia, Hippocratic AI's new partnership

Share This Article